课题基金 / 基金详情

Generation and characterization of human B1 B cells induced by Lin28b reprogramming of adult hematopoietic progenitors

Generation and characterization of human B1 B cells induced by Lin28b reprogramming of adult hematopoietic progenitors
Lin28b 成人造血祖细胞重编程诱导的人类 B1 B 细胞的生成和表征
批准号:
8872222
负责人:
RICHARD R HARDY
金额:
$26.78万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-01-05 至 2016-12-31

项目摘要

项目成果

RICHARD R HARDY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
 DESCRIPTION (provided by applicant): CD5+ B1 B cells in mice constitute a pool of natural autoreactive B cells that carry out many important functions, including clearance of apoptotic cells, making rapid responses to pathogens, and regulating inflammation by secreting IL-10. However, their self-reactive BCRs predispose them to clonal expansion and progression to lymphoma and leukemia in aged animals. Hence, it is important to elucidate the regulatory mechanisms that give rise to these cells both from the point of view of normal and pathological immune responses. An interesting feature of these cells is their predominant origin from a distinctive fetal/neonatal developmental pathway, distinguishing it from most B cell development in bone marrow of adult mice. Recently the role of the Lin28b/Let-7 axis in regulating the switch from fetal to adult development in mice has become apparent, making it possible to generate CD5+ B1 B cells from mouse bone marrow precursors by retroviral transduction of Lin28b. While natural autoreactive B cells also exist in humans, identifying them and elucidating their developmental origins is much more challenging, as CD5 expression in human B cells is more transient and may reflect recent activation, and so is not a useful marker for the fetal B cell lineage. Hence, we have compared Lin28b expression in human fetal and adult hematopoietic progenitors and found that its expression is the same as in mice, present in cord blood progenitors and absent from adult progenitors. These results suggest that the Lin28b/Let-7 axis also functions in human B cell development as a regulatory switch. We will test this hypothesis by characterizing changes in cell surface phenotype, gene expression, and autoreactivity induced in adult B cells when we alter Lin28b/Let-7 expression in human B cell progenitors. Specifically, we will explore: 1) the molecular basis by which Lin28b and Let-7 miR control fate choices in human B cell development; and 2) how adoption of the fetal fate influences the specificity of the B cell antigen receptor. In Aim 1, we will express Lin28b and deplete Let-7 miRNA by Lentiviral transduction of adult human progenitors, differentiating the cells in vitro, then performing flow cytometry to characterize surface protein expression and RNA-Seq to determine genes altered in progenitors and newly-formed B cells. In Aim 2, we will transfer similarly transduced progenitors into immunodeficient NOD/SCID/IL2Rc- mice to facilitate the differentiation of mature B cells. We will compare changes in gene expression in the mature B cell progeny of adult development reprogrammed to resemble fetal type, again by RNA-Seq. We will also test for differences in autoreactivity of the B cell antigen receptors expressed on B cels generated in these mice by normal and Lin28b reprogrammed development. This work will form the basis for further investigation of human B1 B cells, shedding light on the distinctive mechanism of their development, their selection, and their contribution to immunity, autoimmunity, and leukemia. Moreover, gaining insights into the phenotype of human B1 B cells will enable their monitoring during aging, particularly their role in the origin of chronic lymphocytic leukemia.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms regulating the B lymphopoiesis fetal/adult switch
Pre-BCR Function Selecting Novel B Cell Receptors in Chronic Lymphocytic Leukemia
Pre-BCR Function Selecting Novel B Cell Receptors in Chronic Lymphocytic Leukemia
CORE--CELL SORTING
  • 批准号:
    6652208
  • 项目类别:
  • 资助金额:
    $19.62万
  • 财政年份:
    2002
  • 负责人:
    RICHARD R HARDY
  • 依托单位:
海外基金